With Australian specialty pharmaceutical company Race Oncology’s announcement last week that the first patient had been treated with the “lost” drug Bisantrene in a clinical trial for relapsed/refractory acute myeloid […]
There’s no “silver bullet" or “holy grail” when it comes to juggling complex, multi-center clinical trials, says Samantha Sharpe, CCRP, Program Manager, Nationwide Children’s Hospital: Abigail Wexner Research Institute. “There’s […]
Calling out clinical trials as the “most expensive part of drug discovery and development,” Acting U.S. Food and Drug Administration (FDA) Commissioner Dr. Ned Sharpless just told agency staff he’s […]
Site personnel must be empowered to leverage critical thinking when developing and implementing adverse event (AE) reporting procedures in medical device studies, two leading experts say. It might sound like […]
Although advocates for lupus research have counted flawed clinical trial designs and a lack of biomarkers to predict drug response in trials as among the historical barriers to developing better […]